Trials / Completed
CompletedNCT04605991
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY900014 | Administered SC |
| DRUG | Insulin Glargine | Administered SC |
Timeline
- Start date
- 2020-11-04
- Primary completion
- 2022-02-04
- Completion
- 2022-02-04
- First posted
- 2020-10-28
- Last updated
- 2023-03-03
- Results posted
- 2023-03-03
Locations
32 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04605991. Inclusion in this directory is not an endorsement.